rs28934891
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PP5_Very_Strong
The ENST00000398165.8(CBS):c.1330G>A(p.Asp444Asn) variant causes a missense change involving the alteration of a conserved nucleotide. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. D444D) has been classified as Likely benign.
Frequency
Genomes: not found (cov: 0)
Consequence
CBS
ENST00000398165.8 missense
ENST00000398165.8 missense
Scores
2
11
6
Clinical Significance
Conservation
PhyloP100: 7.50
Genes affected
CBS (HGNC:1550): (cystathionine beta-synthase) The protein encoded by this gene acts as a homotetramer to catalyze the conversion of homocysteine to cystathionine, the first step in the transsulfuration pathway. The encoded protein is allosterically activated by adenosyl-methionine and uses pyridoxal phosphate as a cofactor. Defects in this gene can cause cystathionine beta-synthase deficiency (CBSD), which can lead to homocystinuria. This gene is a major contributor to cellular hydrogen sulfide production. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Feb 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM1
In a strand (size 5) in uniprot entity CBS_HUMAN there are 5 pathogenic changes around while only 0 benign (100%) in ENST00000398165.8
PP5
Variant 21-43058862-C-T is Pathogenic according to our data. Variant chr21-43058862-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 126.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr21-43058862-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CBS | NM_000071.3 | c.1330G>A | p.Asp444Asn | missense_variant | 14/17 | ENST00000398165.8 | NP_000062.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CBS | ENST00000398165.8 | c.1330G>A | p.Asp444Asn | missense_variant | 14/17 | 1 | NM_000071.3 | ENSP00000381231 | P1 |
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD3 genomes
Cov.:
0
GnomAD3 exomes AF: 0.000334 AC: 56AN: 167900Hom.: 0 AF XY: 0.000314 AC XY: 28AN XY: 89084
GnomAD3 exomes
AF:
AC:
56
AN:
167900
Hom.:
AF XY:
AC XY:
28
AN XY:
89084
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Cov.: 0
GnomAD4 exome
Cov.:
0
GnomAD4 genome Cov.: 0
GnomAD4 genome
Cov.:
0
Alfa
AF:
Hom.:
TwinsUK
AF:
AC:
2
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
4
ExAC
AF:
AC:
18
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Classic homocystinuria Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 17, 2017 | Across a selection of the available literature, the CBS c.1330G>A (p.Asp444Asn) variant has been identified in at least nine individuals with homocystinuria including four in a homozygous state, three in a compound heterozygous state, and two siblings with the variant in a heterozygous state (Kluijtmans et al. 1996; Kelly et al. 2003; Urreizti et al. 2006; Lefaucheur et al. 2008; Cozar et al. 2011). The variant was also identified in a heterozygous state in the unaffected parents and sister of one of the homozygous individuals (Kluijtmans et al. 1996). The compound heterozygotes all carried a second missense variant on the second allele (Lefaucheur et al. 2008; Cozar et al. 2011). The p.Asp444Asn variant was absent from 80 controls but is reported at a frequency of 0.00134 in the Latino population of the Genome Aggregation Database. Functional studies were performed using cultured fibroblasts from a patient and showed that the p.Asp444Asn variant was not stimulated by physiological levels of S-Adenosylmethionine (AdoMet; a protein which stimulates CBS activity) compared to control fibroblasts, and required increased levels for stimulation (Kluijtmans et al. 1996; Evande et al. 2002). In addition, a study by Hnizda et al. (2012) evaluated protein folding and suggested that C-terminal regulatory domain variants, including the p.Asp444Asn variant, increased protein structural stability and decreased flexibility. Based on the collective evidence, the p.Asp444Asn variant is classified as pathogenic for homocystinuria. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 20, 2019 | NM_000071.2(CBS):c.1330G>A(D444N) is classified as likely pathogenic in the context of homocystinuria, CBS-related. Sources cited for classification include the following: PMID 22267502, 25331909, 20490928, 16245937, 12269827, 8755636, 12007221, 12552044, 14722927, 14972327, 16479318, 18805305 and 21520339. Classification of NM_000071.2(CBS):c.1330G>A(D444N) is based on the following criteria: This variant has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 29, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 16, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | curation | SIB Swiss Institute of Bioinformatics | May 31, 2018 | This variant is interpreted as a Likely Pathogenic, for Cystathionine beta-synthase deficiency, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PS3 => Well-established functional studies show a deleterious effect (PMID:12269827,23974653,20506325,8755636). PM2 => Absent from controls (or at extremely low frequency if recessive; or below the expected carrier frequency if recessive disease or below disease prevalence if dominant disease) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:23974653). PP1 => Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PMID:8755636,). - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 10, 2022 | Reported in association with classical homocystinuria in patients who harbor additional CBS variants (Maclean et al., 2002; Martinez-Gutierrez et al., 2011; Cozar et al., 2011); Belongs to the class of pathogenic variants in the CBS gene that demonstrate significant residual CBS activity by standard in vitro assays, but impair CBS enzyme function by disruption of proper regulation through SAM activation (Mendes et al., 2014a; Alcaide et al., 2015); Published functional studies demonstrate a damaging effect as this variant disrupts CBS protein interaction with S-adenosylmethionine (also called SAM or AdoMet), a cofactor needed for CBS allosteric activation and protein stability, thus causing reduced CBS protein levels and impairing its ability to be properly activated by physiological levels of SAM (Kluijtmans et al., 1996; Evande et al., 2002; Scott et al., 2004; Prudova et al., 2006; Mendes et al., 2014a; Mendes et al., 2014b; Alcaide et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 8755636, 25044645, 22069143, 18805305, 22267502, 20506325, 16245937, 14722619, 12269827, 16614071, 23974653, 14722927, 12552044, 14972327, 21520339, 16479318, 12007221, 20490928, 25331909, 32768567, 31589614, 33726816, 25218699, 21626167) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 20, 2013 | - - |
HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 444 of the CBS protein (p.Asp444Asn). This variant is present in population databases (rs28934891, gnomAD 0.1%). This missense change has been observed in individual(s) with homocystinuria (PMID: 8755636, 14972327, 16479318, 21520339). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 126). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CBS protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CBS function (PMID: 8755636, 14722619, 20490928, 20506325, 22069143, 25044645). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2004 | - - |
Homocystinuria, pyridoxine-responsive Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2004 | - - |
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 25, 2024 | The p.D444N variant (also known as c.1330G>A), located in coding exon 12 of the CBS gene, results from a G to A substitution at nucleotide position 1330. The aspartic acid at codon 444 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been reported in both the compound heterozygous and homozygous states in subjects with pyridoxine responsive homocystinuria (Kluijtmans LA et al. J. Clin. Invest., 1996 Jul;98:285-9; De Lucca M et al. Mol. Genet. Metab., 2004 Mar;81:209-15; Urreizti R et al. J. Hum. Genet., 2006 Feb;51:305-13; Sørensen JT et al. Mol. Genet. Metab., 2016 Mar;117:344-50). Although exhibiting high level of enzyme activity in in vitro assays (Kozich V et al. Hum. Mutat., 2010 Jul;31:809-19; Mayfield JA et al. Genetics, 2012 Apr;190:1309-23; Mendes MI et al. Hum. Mutat., 2014 Oct;35:1195-202), this alteration has been reported to render the mutant protein unresponsive to the allosteric regulator S-adenosylmethionine, which could subsequently affect protein stability and function (Kluijtmans LA et al. J. Clin. Invest., 1996 Jul;98:285-9; Evande R et al. Biochemistry, 2002 Oct;41:11832-7; Scott JW et al. J. Clin. Invest., 2004 Jan;113:274-84; Mendes MI et al. Hum. Mutat., 2014 Oct;35:1195-202). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
CBS-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 17, 2024 | The CBS c.1330G>A variant is predicted to result in the amino acid substitution p.Asp444Asn. This variant has been reported to be causative for homocystinuria (Kluijtmans et al. 1999. PubMed ID: 10364517; Cozar et al. 2011. PubMed ID: 21520339). This variant is reported in 0.13% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/21-44478972-C-T). This variant is interpreted as pathogenic. - |
Homocystinuria Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 30, 2017 | Variant summary: The CBS c.1330G>A (p.Asp444Asn) variant involves the alteration of a conserved nucleotide that lies within the CBS domain (InterPro). 3/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index). This variant was found in 65/192534 control chromosomes at a frequency of 0.0003376, which does not exceed the estimated maximal expected allele frequency of a pathogenic CBS variant (0.0030414). The variant has been reported in numerous patients with CBS-related homocystinuria, including homozygous patients. Functional studies suggest that CBS expression and activity levels are similar to those found in heterozygous individuals, but binding with the necessary cofactor S-adenosylmethionine and the subsequent induction of CBS protein activity is impaired (Mendes_2013). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D;D;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;.;.;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M;M;M
MutationTaster
Benign
A;A;A;A;A;A;A;A;A;A;A;A
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D;D;D
REVEL
Uncertain
Sift
Benign
T;T;T;T
Sift4G
Benign
T;T;T;T
Polyphen
B;B;B;B
Vest4
MVP
MPC
0.42
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at